A detailed history of Jfs Wealth Advisors, LLC transactions in Veracyte, Inc. stock. As of the latest transaction made, Jfs Wealth Advisors, LLC holds 1 shares of VCYT stock, worth $41. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 2 50.0%
Holding current value
$41
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$21.0 - $35.25 $21 - $35
-1 Reduced 50.0%
1 $0
Q1 2024

Apr 30, 2024

BUY
$21.0 - $29.1 $21 - $29
1 Added 100.0%
2 $0
Q4 2023

Feb 07, 2024

SELL
$19.72 - $28.68 $98 - $143
-5 Reduced 83.33%
1 $0
Q2 2023

Aug 07, 2023

SELL
$20.96 - $26.99 $20 - $26
-1 Reduced 14.29%
6 $0
Q1 2023

Apr 19, 2023

BUY
$20.58 - $27.89 $144 - $195
7 New
7 $0
Q2 2022

Aug 02, 2022

SELL
$15.45 - $29.52 $92 - $177
-6 Closed
0 $0
Q1 2022

May 02, 2022

BUY
$21.94 - $42.51 $131 - $255
6 New
6 $0

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.95B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Jfs Wealth Advisors, LLC Portfolio

Follow Jfs Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jfs Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jfs Wealth Advisors, LLC with notifications on news.